Abstract 6-Cyclopropylethynyl-6-trifluoromethyl dihydro-2-oxopurines have been prepared with completely regioselective addition of trimethyl(trifluoromethyl)silane and cyclopropylethynylmagnesium bromide to 1,9-dialkylated 2-oxopurines as key-steps. The target compounds are structurally related to the Non-Nucleoside reverse transcriptase inhibitors Efavirenz and DPC 961.
Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTI) are of increasing importance for the treatment of AIDS (acquired immune deficiency syndrome). 1 One of the NNRTIs approved as anti-HIV drug by the FDA is Efavirenz (Sustiva TM ) ( Fig. 1 ). Several benzopyrimidinone adducts 2 including the second generation Efavirenz analogs DPC 961 and DPC 963 3 (Fig 1) also inhibit reverse transcriptase. DPC 961 exhibits increased potency and favourable plasma serum protein binding compared to Efavirenz. We have previously prepared 6-substituted adducts of 2-oxopurines 4 and as a continuance of this work we now report the synthesis of 6,6-disubstituted 2-oxopurine adducts with structural resemblance to Efavirenz, DPC 961 and DPC 963.
with the 2-oxopurines in the 6-position exclusively to give compounds 2a and 2b in 58 and 62% yields respectively. The regiochemistry of compounds 2 as well as compound 4 below were established by HMQC and HMBC NMR spectroscopy. 4 After purification, adducts 2 were easily rearomatized with MnO2 to give compounds 6. The use of DDQ in these oxidations resulted in complex mixtures and oxidation of crude 2 with MnO 2 was also less successful. The alkynyl substituent in compounds 4a and 4b were introduced when the purines 3a or 3b were reacted with cyclopropylethynylmagnesium bromide (generated in situ from cyclopropylethyne 8 and ethylmagnesium bromide). Again complete regioselectivity in the addition was observed.
Even though both addition reactions took place in the purine 6-position, a carbon substituent can also easily be introduced in the 8-position as demonstrated in the synthesis of the 8-phenylpurine 4c. Bromination of the trifluoro compound 3b gave the 8bromopurine 3c which easily reacted with phenylboronic acid in a Suzuki type coupling.
9,10 The 8-substituted 2-oxopurine 3d did not add cyclopropylethynylmagnesium bromide as described for compound 3a and 3b above, but the reaction with the corresponding organolithium reagent gave the desired adduct 4c in 45% yields. No regioisomers were detected in the reaction mixture. Finally the silicon based protecting groups in compounds 4b and 4c were removed with Me 4 NF to give the DPC 961 analogs 5.
Reverse introduction of the purine 6-substituents was also attempted. Compounds 7 were readily available from addition of the ethynylmagnesium bromide reagent followed by oxidation, but reaction of the alkynylpurines 7 with TMSCF 3 resulted only in complex mixtures. were prepared according to literature procedures. All other reagents were commercially available and used as received. Solvent mixtures are defined as volume ratios (v/v).
1,9-Dibenzyl-1,3,6,9-tetrahydro-6-trifluoromethyl-2H-purin-2-one (2a). To a mixture of 1,9-dibenzyl-1,9-dihydro-2H-purin-2-one (479 mg, 1.5 mmol) and K 2 CO 3 (1.05 g, 7.5 mmol) in dry DMF (50 mL) under N 2 at 0 o C was added dropwise TMSCF 3 (3.8 mL, 7.5 mmol, 2 M solution in THF). The mixture was stirred for 17 h while slowly reaching ambient temperature and diluted with saturated aqueous ammonium chloride (50 mL) and EtOAc (100 mL). The phases were separated and the aqueous phase extracted with EtOAc (2 x 100 mL). The combined organic phases were washed with saturated aqueous sodium chloride (50 mL), dried ( . To a solution of 1,9-dibenzyl-1,3,6,9-tetrahydro-6-trifluoromethyl-2H-purin-2-one (120 mg, 0.31 mmol) in dry benzene (30 mL) was added MnO 2 (1.2 g, 13.8 mmol). The resulting mixture was stirred at ambient temperature for 23 hours, filtered and the product was isolated by flash chromatography on silica gel eluting with EtOAc/hexane (1:1) followed by EtOAc/hexane (3:2) to give the title compound (100 mg, 84%) as colorless crystals; 122-4 °C; 
1,9-Dihydro-1,9-di[(tert-butyldimethylsilyloxy)methyl]-6-trifluoromethyl-2H-purin-2-one (3b).
To a solution of 1,9-di[(tert-butyldimethylsilyloxy)methyl]-1,3,6,9-tetrahydro-6-trifluoromethyl-2H-purin-2-one (105 mg, 0.21 mmol) in dry benzene (25 mL) was added MnO 2 (1.0 g, 11.5 mmol). The resulting mixture was stirred at ambient temperature for 24 hours, filtered and the product was isolated by flash chromatography on silica gel eluting with EtOAc/hexane (1:2) 
8-Bromo-1,9-dihydro-1,9-di[(tert-butyldimethylsilyloxy)methyl]-6-trifluoromethyl-2H-purin-2-one (3c).
To a solution of 1,9-dihydro-1,9-di[(tert-butyldimethylsilyloxy)methyl]-6-trifluoromethyl-2H-purin-2-one (216 mg, 0.44 mmol) in acetic acid (12 mL) and sodium acetate (1.2 g) was added Br 2 (0.050 mL, 0.97 mmol). The solution was stirred for 2 hours at room temperature before diluting with EtOAc (40 mL) and water (40 mL). The resulting mixture was stirred vigorously and aqueous NaHSO 3 (5 %) was added until the solution became colorless. The phases were separated and the aqueous phase extracted with EtOAc (2×40 mL). The combined organic phases were washed with saturated aqueous sodium chloride (30 mL), dried (MgSO 4 ) and evaporated in vacuo. The product was isolated by flash chromatography on silica gel eluting with EtOAc/hexane (1:6) 1,9-Dibenzyl-6-cyclopropylethynyl-1,3,6,9-tetrahydro-6-trifluoromethyl-2H-purin-2-one (4a). To a solution of 1,9-dibenzyl-1,9-dihydro-6-trifluoromethyl-2H-purin-2-one (90 mg, 0.23 mmol) in dry THF (4 mL) under N 2 at -78 o C was added cyclopropylethynylmagnesium bromide [generated in situ by adding cyclopropylethyne (140 mg, 1.27 mmol, 60 % solution in cyclohexane) in dry THF (1 mL) to a solution of ethylmagnesium bromide (1. Cyclopropylethynyl-1,3,6,7-tetrahydro-6-trifluoromethyl-2H-purin-2-one (5a) . To a solution of 6-cyclopropylethynyl-1,9-di[(tert-butyldimethylsilyloxy)methyl]-1,3,6,9-tetrahydro-6-trifluoro-methyl-2H-purin-2-one in dry MeCN (4 mL) was added tetramethylammonium fluoride (1.1 mL, 0.5 M solution in dry MeCN). After 22 hours at ambient temperature the solvent was evaporated in vacuo and the product isolated by flash chromatography on silica gel eluting with CHCl 3 /MeOH (7:1) to give the title compound (27 mg, 69%) as colorless crystals; mp >250 o C (decomp. Cyclopropylethynyl-1,9-dibenzyl-1,3,6,9-tetrahydro-2H-purin-2-one (6a) . To a solution of 1,9-dibenzyl-1,9-dihydro-2H-purin-2-one (158 mg, 0.5 mmol) in dry THF (8 mL) Cyclopropylethynyl-1,9-dibenzyl-1,9-dihydro-2H-purin-2-one (7a) . To a solution of 6-cyclopropylethynyl-1,9-dibenzyl-1,3,6,9-tetrahydro-2H-purin-2-one (60 mg, 0.16 mmol) in dry CH 2 Cl 2 (5 mL) was added MnO 2 (600 mg, 6.9 mmol). The resulting mixture was stirred at ambient temperature for 23 hours, filtered and the product was isolated by flash chromatography on silica gel eluting with CHCl 3 /MeCN (3:1) to give the title compound (40 mg, 67%) as yellow crystals; mp 136-7 o C; Cyclopropylethynyl-1,9-dihydro-1,9-di[(tert-butyldimethylsilyloxy)methyl]-2H-purin-2-one (7b) . To a solution of 1,9-dihydro-1,9-di[(tert-butyldimethylsilyloxy)methyl]-2H-purin-2-one (100 mg, 0.32 mmol) in dry THF (4 mL) under N 2 at -78 o C was added dropwise a solution of cyclopropylethynylmagnesium chloride (0.48 mmol) in dry THF (4 mL) [generated in situ by adding cyclopropylethyne (56 mg, 0.51 mmol, 60 % solution in cyclohexane) in dry THF (2 mL) to a solution of isopropylmagnesium chloride (0.24 mL, 0.48 mmol, 2.0 M solution in THF) in dry THF (2 mL) under N 2 and refluxing the resulting mixture for 2 hours before cooling to ambient temperature]. After stirring for 1 hour at -78 o C and 20 hours at ambient temperature, saturated aqueous ammonium chloride (10 mL) and CH 2 Cl 2 (20 mL) were added to the reaction mixture and the phases were separated. The organic phase was extracted with saturated sodium hydrogen carbonate (10 mL), dried (MgSO 4 ) and evaporated in vacuo. The crude product (6b) was dissolved in dry benzene (20 mL). DDQ (72 mg, 0.32 mmol) was added and the resulting mixture was stirred at ambient temperature for 3 hours, filtered and the solvent was evaporated in vacuo. 
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